STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1061 by analyst upside · 2026-08-13
MGNX
MacroGenics, Inc.
Healthcare · Market Cap $256M · P/E 0x
ANALYST PRICE TARGET
+67.9%
implied upside to consensus target
Current Price $4.02
Consensus Target $6.75
Bull Target $9.0
Bear Target $4.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
1
Hold
2
Sell
0
52-Week Low $1.29
52-Week High $5.08
YTD Return +149.7%
FUNDAMENTALS
Market Cap $256M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $157M
Profit Margin -44.8%
52-WEEK RANGE
52-Week Low $1.29
52-Week High $5.08
Current Price $4.02
Bear Target $4.0
Bull Target $9.0
● Now $4.02 ● Target $6.75
TRADING DATA
Avg Volume 1.0M
YTD Return +149.7%
Analyst Count 4
Consensus Buy
Upside to Target +67.9%
Last Updated 2026-08-13

ANALYST SUMMARY

MacroGenics, Inc. (MGNX) is currently trading at $4.02 with a Wall Street consensus price target of $6.75, implying potential upside of 67.9% over the next 12 months. 4 analysts currently cover MGNX, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $4.0.

MGNX operates in the Healthcare sector with a market capitalisation of $256M. The stock is up 149.7% year-to-date and is currently trading near the upper end of its 52-week range of $1.29 – $5.08.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MGNX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-04-20 Building track record
B. Riley Securities ↑ Upgrade
Neutral → Buy 2026-04-10 17% win rate (6 calls)
Barclays - Reiterated
Overweight → Overweight 2026-03-10 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2025-11-03 31% win rate (48 calls)
Leerink Partners - Reiterated
Outperform → Outperform 2025-08-15 29% win rate (7 calls)
B. Riley Securities - Reiterated
Neutral → Neutral 2025-05-20 17% win rate (6 calls)
Stifel - Reiterated
Hold → Hold 2025-05-14 Building track record
Barclays - Reiterated
Overweight → Overweight 2025-05-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
24
out of 100
Coverage depth
12/30
Consensus clarity
5/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →